- Date 25 May 2016
- Documents : 4
- Economic analysis
- History
Listen
KYPROLIS (carfilzomib), antineoplastic
ONCOLOGY - New medicinal product
Opinions on drugs -
Posted on
Nov 03 2016
Reason for request
Inclusion
Minor improvement in the treatment of patients with multiple myeloma who have received at least one line of treatment, in combination with lenalidomide and dexamethasone, when compared with the combination of lenalidomide and dexamethasone.
- KYPROLIS has a Marketing Authorisation in combination with lenalidomide and dexamethasone in the treatment of multiple myeloma in adults who have had at least one previous line of treatment.
- The efficacy of Kyprolis combined with lenalidomide and dexamethasone has been demonstrated on progression free survival when compared to the combination of lenalidomide and dexamethasone alone..
- Cardiac function monitoring is necessary with KYPROLIS treatment, especially in patients who have already suffered a myocardial lesion.
Clinical Benefit
| Substantial |
- |
Clinical Added Value
| minor |
- |
Therapeutic use
|
- |
-
Economic analysis
English version
Contact Us
Évaluation des médicaments
